Pancreatic Cancer Research

Pancreatic cancer research explores early detection biomarkers, stromal targeting, KRAS-directed therapy, and neoadjuvant treatment approaches.

Our Pancreatic Cancer Analysis

• September 24, 2026JAMA Oncology

  Modifiable Risk Factors Account for an Estimated 84% of the Male–Female Cancer Gap in China but 26% in the UK

  A multicohort analysis of 589,766 adults aged 40 to 74 years without prior cancer, drawn from the Shanghai Men’s Health Study, the Shanghai Women’s Health Study and UK Biobank, estimated how much of the higher cancer incidence in males is attributable to 11 lifestyle factors and health conditions.

• September 22, 2026Nature MedicinePATHFINDER 2 (NCT05155605)

  Multi-Cancer Blood Test Reaches 60% Positive Predictive Value and 99.6% Specificity in Largest Prospective Screening Study to Date

  PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.

• August 20, 2026JAMA Oncology

  Industry Now Outpaces Federal Cancer Trial Sponsorship Nearly 5 to 1 — And the Gap Is Widening

  A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.

• August 20, 2026Journal of Clinical OncologyNRG Oncology/RTOG 0848 (NCT01013649)

  Adjuvant Chemoradiotherapy Misses Overall Survival Goal, but May Help Node-Negative Pancreatic Cancer

  The Step 2 randomization of NRG Oncology/RTOG 0848, a phase III trial of 354 patients with resected pancreatic head adenocarcinoma, found that adding chemoradiotherapy (CXRT) to adjuvant chemotherapy did not significantly improve overall survival across the full study population.

• August 18, 2026Nature MedicineNCT05379985 (Phase 1/2)

  Genomic Profiling Reveals How Pancreatic Cancer Escapes RAS(ON) Inhibitor Daraxonrasib

  Paired ctDNA profiling of 44 patients with RAS-mutant metastatic pancreatic cancer who progressed on daraxonrasib monotherapy found acquired RAS pathway alterations in 26 of 44 patients (59%), with mutant KRAS amplification the dominant mechanism (36%, 16 of 44).

• July 9, 2026Nature MedicineHRS-4642 + AG (NCT06520488)

  Intravenous KRAS-G12D Inhibitor HRS-4642 Achieves a 63% Response Rate in First-Line Pancreatic Cancer: A Phase 1b/2 Trial

  Open-label, single-arm phase 1b/2 trial of HRS-4642 — an intravenous, liposomal-nanoparticle KRAS-G12D inhibitor — added to gemcitabine and nab-paclitaxel (the "AG" backbone) in advanced KRAS-G12D-mutant pancreatic ductal adenocarcinoma (PDAC); 68 patients screened, 31 treated, 30 treatment-naive